Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2026-01-21 00:00:00 ET · period of report 2026-01-20 · accession 0001831410-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-21 | 2026-01-20 | OLMA | Harmon Cyrus | Dir | S - Sale | $26.88 | -10.0K | 727.8K | -1% | -$268.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-20 | S | D | 10,000 | $26.88 | 727,770 | D | — | — | (F1) 2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |